LY-272,015

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
LY-272,015
LY-272,015 structure.png
Systematic (IUPAC) name
1-(3,4-dimethoxybenzyl)-6-methyl-2,3,4,9-tetrahydro-1H-β-carboline
Identifiers
CAS Number 172895-15-7
PubChem CID: 9929424
ChemSpider 8105055
Synonyms LY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole
Chemical data
Formula C21H24N2O2
Molecular mass 336.426 g/mol
  • c4cc(C)cc3c4nc2c3CCNC2Cc(cc1OC)ccc1OC
  • InChI=1S/C21H24N2O2/c1-13-4-6-17-16(10-13)15-8-9-22-18(21(15)23-17)11-14-5-7-19(24-2)20(12-14)25-3/h4-7,10,12,18,22-23H,8-9,11H2,1-3H3
  • Key:GDAJGLDMCDMPIR-UHFFFAOYSA-N
  (verify)

LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models,[1][2] and is also used in research into the other functions of the 5-HT2B receptor.[3]


References

  1. ↑ Watts SW, Fink GD. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. American Journal of Physiology. 1999 Mar;276(3 Pt 2):H944-52. PMID 10070078
  2. ↑ Russell A, Banes A, Berlin H, Fink GD, Watts SW. 5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat. Journal of Pharmacology and Experimental Therapeutics. 2002 Oct;303(1):179-87. PMID 12235249
  3. ↑ Günther S, Maroteaux L, Schwarzacher SW. Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro. Journal of Neurobiology. 2006 Aug;66(9):949-61. doi:10.1002/neu.20253 PMID 16758492


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=LY-272,015&oldid=718906990"